한글목차

세계의 폐수종 치료 시장은 2030년까지 24억 달러에 달할 전망

2023년에 21억 달러로 추정되는 세계의 폐수종 치료 시장은 분석 기간인 2023-2030년 CAGR 1.7%로 성장하며, 2030년에는 24억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 심원성 폐수종 치료는 CAGR 1.9%를 기록하며, 분석 기간 종료까지 15억 달러에 달할 것으로 예측됩니다. 비심원성 폐수종 치료 부문의 성장률은 분석 기간에 CAGR 1.4%로 추정됩니다.

미국 시장은 5억 8,410만 달러, 중국은 CAGR 3.7%로 성장 예측

미국의 폐수종 치료 시장은 2023년에 5억 8,410만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 4억 6,300만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년의 CAGR은 3.7%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.3%와 1.2%로 예측됩니다. 유럽에서는 독일이 CAGR 약 0.7%로 성장할 것으로 예측됩니다.

세계의 폐수종 치료시장 - 주요 촉진요인과 동향 정리

폐수종은 폐의 공기주머니에 액체가 축적되어 가스 교환 장애와 호흡 곤란을 유발하는 심각한 질환입니다. 이 상태는 울혈성심부전, 급성 호흡곤란 증후군(ARDS), 높은 고도, 특정 독소 및 약물 노출 등 다양한 원인으로 인해 발생할 수 있습니다. 폐수종 치료의 1차적인 목표는 과도한 체액을 제거하고 산소 공급을 개선하며 근본적인 원인을 해결하는 것입니다. 치료적 접근은 일반적으로 환자별 병태와 중증도에 따라 약리학적 개입과 비약리학적 개입을 결합합니다.

폐수종의 약리학적 치료에는 주로 신장에서 배설을 촉진하여 체액 저류를 억제하는 푸로세미드와 같은 이뇨제가 포함됩니다. 니트로글리세린과 같은 혈관 확장제는 혈관내 압력을 낮추어 심장의 작업량을 줄이고 폐의 체액 축적을 완화하는 데 도움이 될 수 있습니다. 폐수종의 원인이 심부전인 경우 심장 기능을 개선하기 위해 ACE 억제제, 베타 차단제 등의 약물을 처방합니다. 비약물 요법으로는 혈액내 산소 농도를 개선하기 위한 산소 요법, 심한 경우 호흡을 보조하기 위한 기계적 인공호흡을 시행합니다. 또한 염분 섭취량 감소, 수분 균형 관리 등 생활습관 개선은 폐수종이 발생하기 쉬운 만성질환을 가진 환자의 장기적인 관리에 필수적인 요소입니다.

폐수종 치료 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 폐수종의 주요 원인인 심혈관 질환의 유병률 증가로 인해 효과적인 치료에 대한 수요가 크게 증가하고 있습니다. 둘째, 의학 연구의 발전으로 더 나은 효과와 안전성 프로파일을 제공하는 새롭고 개선된 약리학적 치료법이 개발되고 있습니다. 심장 관련 질환과 호흡기 질환에 취약한 세계 인구의 고령화는 시장 성장을 더욱 촉진하고 있습니다. 또한 신흥 시장의 의료 인프라 확대와 고급 의료에 대한 접근성이 높아짐에 따라 폐수종 치료의 가용성이 증가하고 있습니다. 제약회사와 연구기관의 전략적 제휴는 혁신적인 치료법의 발견과 상용화를 가속화하고 있습니다. 마지막으로 의료진과 환자들의 폐수종에 대한 인식과 조기 진단에 대한 인식이 높아지면서 시의적절하고 효과적인 치료 개입에 대한 수요가 증가하여 시장의 성장 궤도를 공고히 하고 있습니다.

조사 대상 기업의 예(주목 86사)

• Bayer AG
• Citius Pharmaceuticals, Inc.
• Edesa Biotech
• Exponential Biotherapies
• Genentech, Inc.
• Lupin Ltd.
• Pantherna Therapeutics GmbH
• Pfizer Inc.
• Qx Therapeutics, Inc.
• Sun Pharmaceutical Industries Ltd.;

목차

제1장 조사 방법

제2장 개요

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장의 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 스페인
• 러시아
• 기타 유럽
• 아시아태평양
• 호주
• 인도
• 한국
• 기타 아시아태평양
• 라틴아메리카
• 아르헨티나
• 브라질
• 멕시코
• 기타 라틴아메리카
• 중동
• 이란
• 이스라엘
• 사우디아라비아
• 아랍에미리트
• 기타 중동
• 아프리카

제4장 경쟁

영문목차

Global Pulmonary Edema Therapeutics Market to Reach US$2.4 Billion by 2030

The global market for Pulmonary Edema Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Cardiogenic Pulmonary Edema Therapeutics, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Non-Cardiogenic Pulmonary Edema Therapeutics segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$584.1 Million While China is Forecast to Grow at 3.7% CAGR

The Pulmonary Edema Therapeutics market in the U.S. is estimated at US$584.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$463.0 Million by the year 2030 trailing a CAGR of 3.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.3% and 1.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Global Pulmonary Edema Therapeutics Market - Key Drivers and Trends Summarized

Pulmonary edema is a serious medical condition characterized by the accumulation of fluid in the lungs' air sacs, leading to impaired gas exchange and difficulty breathing. This condition can result from various causes, including congestive heart failure, acute respiratory distress syndrome (ARDS), high altitude, and exposure to certain toxins or medications. The primary goal of pulmonary edema treatment is to remove the excess fluid, improve oxygenation, and address the underlying cause. Therapeutic approaches typically involve a combination of pharmacological and non-pharmacological interventions, tailored to the patient's specific condition and severity.

Pharmacological treatments for pulmonary edema primarily include diuretics, such as furosemide, which help to reduce fluid accumulation by promoting its excretion through the kidneys. Vasodilators like nitroglycerin are also used to decrease the pressure in the blood vessels, reducing the workload on the heart and helping to alleviate fluid buildup in the lungs. In cases where pulmonary edema is caused by heart failure, medications like ACE inhibitors or beta-blockers may be prescribed to improve heart function. Non-pharmacological treatments can include oxygen therapy to improve oxygen levels in the blood and mechanical ventilation in severe cases to support breathing. Additionally, lifestyle modifications, such as reducing salt intake and managing fluid balance, are essential components of long-term management for patients with chronic conditions that predispose them to pulmonary edema.

The growth in the pulmonary edema therapeutics market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases, which are a major cause of pulmonary edema, has significantly boosted the demand for effective treatments. Secondly, advancements in medical research have led to the development of new and improved pharmacological therapies that offer better efficacy and safety profiles. The aging global population, which is more prone to heart-related conditions and respiratory issues, has further fueled market growth. Additionally, the expansion of healthcare infrastructure and access to advanced medical care in emerging markets has increased the availability of pulmonary edema treatments. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the discovery and commercialization of innovative therapies. Lastly, heightened awareness and early diagnosis of pulmonary edema among healthcare professionals and patients have driven the demand for timely and effective therapeutic interventions, solidifying the market's growth trajectory.

Select Competitors (Total 86 Featured) -

• Bayer AG
• Citius Pharmaceuticals, Inc.
• Edesa Biotech
• Exponential Biotherapies
• Genentech, Inc.
• Lupin Ltd.
• Pantherna Therapeutics GmbH
• Pfizer Inc.
• Qx Therapeutics, Inc.
• Sun Pharmaceutical Industries Ltd.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Pulmonary Edema Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Cardiovascular and Respiratory Diseases Drives Demand for Pulmonary Edema Therapeutics
  • Advancements in Diagnostic Technologies Enhance Early Detection and Treatment
  • Growing Awareness of Respiratory Health Boosts Market Demand for Therapeutics
  • Rising Incidence of Acute Pulmonary Edema and Influence on Market Dynamics
  • Development of Targeted Therapies and Precision Medicine Propels Market Growth
  • Advances in Biotechnology Drive Development of Novel Pulmonary Edema Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pulmonary Edema Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pulmonary Edema Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Cardiogenic Pulmonary Edema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Cardiogenic Pulmonary Edema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Cardiogenic Pulmonary Edema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Non-Cardiogenic Pulmonary Edema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Non-Cardiogenic Pulmonary Edema by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Non-Cardiogenic Pulmonary Edema by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• JAPAN
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• CHINA
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• EUROPE
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Pulmonary Edema Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• FRANCE
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• GERMANY
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: Australia 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• INDIA
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 113: India Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: India 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 116: India Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: India 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: South Korea 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Pulmonary Edema Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Argentina 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Brazil 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Mexico 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Rest of Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Pulmonary Edema Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: Iran 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: Israel 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Saudi Arabia 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: UAE 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
• AFRICA
  • Pulmonary Edema Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Pulmonary Edema Therapeutics by Type - Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Africa 16-Year Perspective for Pulmonary Edema Therapeutics by Type - Percentage Breakdown of Value Sales for Cardiogenic Pulmonary Edema and Non-Cardiogenic Pulmonary Edema for the Years 2014, 2024 & 2030
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Pulmonary Edema Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Pulmonary Edema Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION